drug
galcanezumab
Marketedupdated 3mo agoby Eli Lilly and Co
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying galcanezumab
- phase4Novel Insight Into Migraine Pathophysiolgy and Galcanezumab Mechanisms of Action
- phase3A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
- phase4Anti-CGRP for Inflammation and Pain Modulation in Small Fiber Neuropathy/Fibromyalgia
- phase3A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
- —Emgality for Migraine in Breastmilk
- phase4The Effect of Galcanezumab-gnlm on Post-Traumatic, Migrainous Headaches
- phase2Galcanezumab for Vestibular Migraine
- phase4A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine
News(1)
- Study data convince Lundbeck to push new migraine drug forwardA possible alternative to “anti-CGRP” medications, the drug didn’t meet some analysts’ expectations in mid-stage testing but still convinced Lundbeck to pursue further development.biopharma_dive · 2mo ago
Data sources
last refreshed 16m ago
Found something off?
comments(0)
5-min edit window · permanent after that